Strategic Acquisitions Leverage InSphero's recent acquisitions of PhenoVista Biosciences and Sun Bioscience/ DOPPL to position partnerships or co-development opportunities in high-content imaging, organoid technologies, and Gri3D-based platforms for broader drug safety and efficacy testing services.

Expanded Platform Target customers with interest in liver safety, liver disease, islet biology, oncology, and immunology by positioning InSphero’s integrated 3D spheroid models and upcoming 3D InSight GI toxicity platform as comprehensive preclinical screening solutions that reduce late-stage failures.

Growth Momentum Capitalize on rapid growth signals and leadership in 3D in vitro models to pursue collaborations with pharma and biotech firms seeking faster, more robust translational data, offering co-development, custom assay creation, and high-content imaging services.

Strategic Partnerships Explore partnerships with digital pathology and imaging players (e.g., PharmaNest, Genome Biologics) to integrate advanced analytics, enabling end-to-end workflows from organoid/3D models to phenotypic readouts and data-driven decision making.

Global Expansion Opportunity to engage multinational biotech companies expanding R&D pipelines, offering scalable 3D platforms and services that align with regulatory-grade safety and efficacy testing to support clinical translation across diverse therapeutic areas.